[Federal Register Volume 72, Number 61 (Friday, March 30, 2007)]
[Notices]
[Page 15137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-5917]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting: Vaccine Safety Evaluation: Post-Marketing Surveillance

AGENCY: Department of Health and Human Services, Office of the 
Secretary.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Vaccine Program Office is hereby giving notice 
that, in conjunction with the National Institutes of Health, the Food 
and Drug Administration, the Centers for Disease Control and 
Prevention, and the Health Resources and Services Administration, is 
hosting a 2-day meeting titled: Vaccine Safety Evaluation: Post-
marketing Surveillance. The meeting is open to the public.

DATES: The meeting will be held on April 10, 2007, from 9 a.m. to 6 
p.m., and on April 11, 2007, from 9 a.m. to 5 p.m.

ADDRESS: National Institutes of Health, 9000 Rockville Pike, Natcher 
Auditorium--Building 45, Bethesda, Maryland 20892.

FOR FURTHER INFORMATION CONTACT: Dr. Kenneth Bart, National Vaccine 
Program Office, Department of Health and Human Services, Room 443-H, 
Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, 
DC 20201; (202) 690-5566, <a href="/cdn-cgi/l/email-protection#f2b9979c9c97869adc90938086b29a9a81dc959d84"><span class="__cf_email__" data-cfemail="a8e3cdc6c6cddcc086cac9dadce8c0c0db86cfc7de">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: The principal theme of the meeting is, 
``What should an ideal post-licensure vaccine safety system be?'' As 
part of a continuing effort to maximize the safety of vaccines, the 
meeting will review what the United States is currently doing in post-
marketing surveillance of vaccine safety and their strengths and 
weaknesses. In addition, with the participation of international 
experts, we expect to learn about what has worked in other countries, 
new methodologies that are being experimented with, and areas where new 
research could be directed.
    Public attendance at the meeting is limited to space available. 
Individuals must provide a photo ID for entry onto the National 
Institutes of Health (NIH) campus. Individuals who plan to attend and 
need special assistance, such as sign language interpretation or other 
reasonable accommodations, should notify the designated contact person. 
Members of the public will have the opportunity to provide comments at 
the meeting. Public comment will be limited to five minutes per 
speaker. Any members of the public who wish to have printed material 
distributed to meeting attendees should submit materials to the contact 
person listed above prior to close of business April 2, 2007. 
Additionally, should you wish to make a brief presentation, please 
contact Dr. Kenneth Bart using the contact information provided above.
    Due to security measures at the NIH campus, pre-registration will 
greatly ease entrance onto the campus. Any individual who wish to 
attend the meeting should submit that request via e-mail to <a href="/cdn-cgi/l/email-protection#5b352d2b3476363e3e2f32353c281b383435282f3e37373a3c29342e2b75383436"><span class="__cf_email__" data-cfemail="8de3fbfde2a0e0e8e8f9e4e3eafecdeee2e3fef9e8e1e1eceaffe2f8fda3eee2e0">[email protected]</span></a>. Please note that registration must be 
completed by close of business on April 2, 2007.
    Additional information, including a draft agenda, can be found at: 
http://www.hhs.gov/nvpo.

    Dated: March 27, 2007.
Bruce Gellin,
Director, National Vaccine Program Office.
[FR Doc. E7-5917 Filed 3-29-07; 8:45 am]
BILLING CODE 4150-44-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>